ArticleFrontiers in cardiovascular medicine2026
Global, regional, and national burden and projections of severe heart failure attributable to hypertensive, ischemic, and rheumatic heart diseases: an analysis from the global burden of disease study 2021.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global Incidence of Cardiovascular Diseases Attributable to Chronic Obstructive Pulmonary Disease: A Modelling Study Based on GBD 2021.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe heart failure (SHF) caused by hypertensive heart disease (HHD), ischemic heart disease (IHD), and rheumatic heart disease (RHD) remains a significant global public health concern. Accurate assessments of the global and regional burdens, trends, and health inequalities related to these diseases are critical for formulating targeted health policies and interventions. Methods: Data on the prevalence and years lived with disability (YLDs) due to severe heart failure resulting from HHD, IHD, and RHD from 1990 to 2021 were extracted from the Global Burden of Disease (GBD) Study 2021. Trends were analyzed according to age-standardized rates (ASRs) and sociodemographic index (SDI) stratifications. Predictions for 2022-2040 were generated using Nordpred modeling and validated with the Bayesian Age-Period-Cohort (BAPC) model. Results: In 2021, prevalent cases for severe heart failure attributable to HHD, IHD, and RHD reached 4.07 million, 6.24 million, and 0.74 million, respectively, with corresponding age-standardized prevalence rates (ASPR) of 48.3, 74.4, and 9.2 per 100,000. Compared with 1990, cases increased by 170.3% for HHD, 140.7% for IHD, and 39.0% for RHD. YLDs rose to 700,272 (HHD), 1,075,512 (IHD), and 129,155 (RHD), respectively. The greatest burdens occurred in Eastern Sub-Saharan Africa for HHD (ASPR: 95.0), North Africa and the Middle East for IHD (ASPR: 103.1), and South Asia for RHD (ASPR: 21.0). Projections indicate continued increases in prevalent cases and YLDs for all conditions, with stable or slightly rising standardized rates, highlighting persistent regional and gender inequalities. Conclusion: Severe heart failure burdens related to HHD, IHD, and RHD are increasing globally, influenced significantly by demographic shifts and socioeconomic disparities. Urgent implementation of context-specific preventive and healthcare strategies is essential to address health inequalities and reduce the future burden of severe heart failure worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.